This is a surprise. There was good reason why $INCY purchased EP262 for $750m, and this includes the signaling blockades you mentioned. A lot of pathways involved in both CIndU and CSU, and translation isn’t guaranteed. Can look at dupixent failure in CIndU. Still waiting for EVO756 results, but this could just be part of the natural learning curve of MRGPRX2 function in humans. At the same time, the consistency of EP262 and EVO756 CIndU results can’t be ignored. The target has efficacy, it’s about finding the right indication.

MIRUM AND INCYTE CRUSH PHASE 2 IN FOP Mirum Pharmaceuticals $MIRM and Incyte $INCY dropped strong pivotal Phase 2 results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva, with the FDA already granting Priority Review. 🔹 99.9% reduction in new HO lesion volume vs placebo 🔹 81% fewer patients developed new lesions at week 24 🔹 Priority Review with September 26 PDUFA date

$mirm $incy Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva

Las mejores empresas para añadir esta semana 🔌 $APH $ANET $DY — IA 💸 $DAVE $RSI — fintech 🧬 $INCY — biotech 🚀 $OUST $UMAC — lidar drones ✈️ $AIR — aeroespacial 🪙 $AYA — oro & plata Más en la comunidad ➡️t.me/PYTTrading 📲

The Storybarn is closed on Monday, But don't worry! We are back in action for the rest of the week. On Wednesday we're putting on our exploring boots for our Incy Wincy Wanders sessions. Incy Wincy and Drop in sessions are here to end the week, for the little ones to dream big!

$MIRM and $INCY Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva businesswire.com/news/home/2…

I remember watching these guys (was it only a singular guy?) when I was an incy bitsy toddler.

Eli Lilly ($LLY) just dropped a clinical data bomb at EHA 2026, threatening to completely disrupt the $3B myelofibrosis market currently dominated by Incyte ($INCY) and rewriting the competitive benchmarks for Chinese players like Zelgen ($688266.SH). Lilly’s newly acquired Type II JAK2 inhibitor, AJ1-11095, posted spectacular P1 data in pre-treated patients, completely obliterating historical salvage-line response rates of 0% to 32%: • SVR35 (Spleen Volume Reduction): 70% • TSS50 (Total Symptom Score): 70% at Week 12 • Mutation reduction achieved across all variants (JAK2, MPL, and CALR) While Incyte’s pipeline asset is restricted to CALR mutations—limiting its addressable population to just a third of patients—Lilly's asset offers full all-comer coverage with massive efficacy gains. This shifts the global paradigm. In China, Zelgen ($688266.SH) has built a domestic stronghold with its first-generation JAKi Jaktinib, but Lilly’s structural move toward Type II conformational selectivity represents a massive technological leap. Lilly is successfully weaponizing its massive GLP-1 cash flows to buy up highly de-risked, Best-in-Class oncology assets. $LLY $INCY $688266.SH $XBI $IBB

é sempre uma marmita de incel se masturbando com porno gay pq não consegue se satisfazer com o pau do incy

바이오 및 제약 섹터의 임상 발표가 줄을 이으며 제약 바이오주 중심의 기대감이 고조되는 분위기입니다. ​CRNX : 두 개의 임상 파이프라인 모멘텀 중첩 ​INCY : 진행 중인 임상 2상 연구의 긍정적 결과 ​Https://shorttermstock.tisto… ​#미국주식 #CRNX #INCY

$INCY $MIRM Announce Positive Pivotal Phase 2 Data from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva. #ENDO26 businesswire.com/news/home/2…

$MIRM $INCY more bio headlines here Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva "Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for zilurgisertib in FOP under Priority Review"

Looks like all our planned plays will front run due to news over weekend $META $INCY $INTC $FCX $COPX $AMKR $CPNG I got early into CPNG INTC Stock buys Friday but no option positions yet

$INCY $MIRM Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva _ 99.9% reduction in total volume of new HO lesions in patients receiving zilurgisertib versus placebo at Week 24 (nominal p-value<0.0001). - Reduction in total existing HO lesion volume compared with an increase observed in placebo-treated patients at Week 24 (nominal p-value=0.004). - Among patients receiving zilurgisertib, no new HO lesions were observed and total HO lesion volume continued to decrease from Week 24 to Week 48. - Among patients who crossed over from placebo to zilurgisertib, no new HO lesions were observed and total HO lesion volume decreased from Week 24 to Week 48. stocktitan.net/news/INCY/mir…

$INCY 0.67% today Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva More Info: pryzm.ozmosi.com/product/210…

$INCY The volume for Incyte stock increased for four consecutive days, resulting in a record-breaking daily growth of 75% of the 65-Day Volume Moving Average $XLV $SPY tickeron.com/news/90568921-t…

PRLD / INCY also have JAK2 V617F mutant selective inhibitors that could be competitive